Signals Blog
Menu

David Brindley

David is an international thought-leader in the translation of life-science innovations into commercially viable products and services. His expertise spans the ‘Valley of Death,’ encompassing regulation, basic science, process engineering and finance. This distinctive skill set positions David at the forefront of socially responsible investments – in particular initiatives that make impactful contributions to global health. David currently holds a joint appointment between the University of Oxford and the Harvard Stem Cell Institute and is an active Fellow of the Royal Institution of Great Britain and the Royal Society for the Advancement of Arts and Manufacturing. In addition to being an Editorial Board member of a range of international academic and industrial journals, David is also a founder of Translation Ventures, a boutique consultancy that is actively engaged in maximizing the financial and societal value realized from cutting edge scientific innovations. Disclosure: David A Brindley has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in any postings apart from those disclosed. D.A.B. is subject to the CFA Institute’s Codes, Standards, and Guidelines, and as such, the author must stress that his contributions to this site are provided for academic interest only and must not be construed in any way as an investment recommendation.

Posts by: David


If cell therapy isn’t about the cells or the therapy, what is it about?

. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate.   Both the IBC Cell Therapy Bioprocessing (ICTB) conference and the Stem Cells and Regenerative Medicine Congress (SCRMC) took place recently. The conferences shared several common themes: one being the presence of a significant focus […]

Revolution and reimbursement in the cell therapy industry

. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate   In the early 1770s, Britain faced a significant financial dilemma. One of its most important commercial institutions, the East India Company, had come into considerable financial problems; a large quantity of tea was being […]

Of seismic waves and closing days: take home messages

. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. There were two momentous events on the night of August 23, 2014. First, the inaugural Rejuvenation Biotechnology conference drew to a close. Second, the largest earthquake in nearly 25 years […]

Explosive growth in cell therapy just around the corner?

. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute.   Assume a single bacterium weighs one thousand billionth of a gram. If it, and each of its progeny, divides once every 20 minutes then the population will reach approximately […]

Life, death and regulation

. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute.   Consider this question: if I gave you the option to take a drug offering a 100 percent chance of survival to average life expectancy at which time you would […]